Free Trial

This company recently went public with an IPO on Friday, May 1st 2026. They issued 14,160,000 shares at $16.00 - $18.00 per share. We will continue to update data for SPTX as it becomes available.

Seaport Therapeutics (SPTX) 10K Form and Latest SEC Filings 2026

$16.00 -1.00 (-5.88%)
As of 05/5/2026 04:00 PM Eastern

Latest Seaport Therapeutics SEC Filings & Recent Activity

Seaport Therapeutics (NASDAQ:SPTX) has submitted 33+ documents to the U.S. Securities and Exchange Commission (SEC) since 2024. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 4 submitted on May 4, 2026.

Form 4
Seaport Therapeutics, Inc. Reports Ownership Change on May. 4, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

Seaport Therapeutics SEC Filing History

Browse Seaport Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/04/2026 5:07 PM
Chen Michael Cunyuan (2127529) Reporting
Seaport Therapeutics (2042347) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 5:08 PM
Gladstein Lana (2127496) Reporting
Seaport Therapeutics (2042347) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 5:09 PM
PETERSON SANDRA E (1192752) Reporting
Seaport Therapeutics (2042347) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 5:10 PM
Seaport Therapeutics (2042347) Issuer
Wheadon David E. (1789507) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 5:13 PM
Seaport Therapeutics (2042347) Issuer
White Lauren (1864430) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 5:14 PM
HEALY JAMES (1245624) Reporting
Seaport Therapeutics (2042347) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 5:18 PM
Seaport Therapeutics (2042347) Issuer
Zohar Daphne (1727388) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 5:00 PM
Mates Sharon (1585699) Reporting
Seaport Therapeutics (2042347) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 5:01 PM
Loebel Antony (1818770) Reporting
Seaport Therapeutics (2042347) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 5:02 PM
HOMBACH ROBERT J. (1496182) Reporting
Seaport Therapeutics (2042347) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 5:02 PM
ARCH Venture Fund XII, L.P. (1906837) Reporting
ARCH Venture Partners XII, L.P. (1979765) Reporting
ARCH Venture Partners XII, LLC (1979548) Reporting
Burow Kristina (1569248) Reporting
CRANDELL KEITH (1219039) Reporting
GILLIS STEVEN (1229592) Reporting
NELSEN ROBERT (1219042) Reporting
Seaport Therapeutics (2042347) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 5:05 PM
PAUL STEVEN M (1237564) Reporting
Seaport Therapeutics (2042347) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 5:06 PM
Seaport Therapeutics (2042347) Issuer
Torres Denice (1820278) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2026 4:31 PM
Seaport Therapeutics (2042347) Filer
Form 424B4
04/30/2026 8:35 PM
PureTech Health plc (1782999) Reporting
PureTech Health plc (1782999) Reporting
PureTech LYT, Inc. (2131815) Reporting
Seaport Therapeutics (2042347) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/30/2026 7:07 PM
Gladstein Lana (2127496) Reporting
Seaport Therapeutics (2042347) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/30/2026 7:09 PM
ARCH Venture Fund XII, L.P. (1906837) Reporting
ARCH Venture Partners XII, L.P. (1979765) Reporting
ARCH Venture Partners XII, LLC (1979548) Reporting
Burow Kristina (1569248) Reporting
CRANDELL KEITH (1219039) Reporting
GILLIS STEVEN (1229592) Reporting
NELSEN ROBERT (1219042) Reporting
Seaport Therapeutics (2042347) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/30/2026 7:09 PM
PAUL STEVEN M (1237564) Reporting
Seaport Therapeutics (2042347) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/30/2026 7:10 PM
HEALY JAMES (1245624) Reporting
Seaport Therapeutics (2042347) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/30/2026 7:10 PM
Seaport Therapeutics (2042347) Issuer
Wheadon David E. (1789507) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/30/2026 7:11 PM
Pitts Jason (1821346) Reporting
Seaport Therapeutics (2042347) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/30/2026 7:14 PM
Seaport Therapeutics (2042347) Issuer
White Lauren (1864430) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/30/2026 7:14 PM
Seaport Therapeutics (2042347) Issuer
Torres Denice (1820278) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/30/2026 7:14 PM
Mates Sharon (1585699) Reporting
Seaport Therapeutics (2042347) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/30/2026 7:17 PM
Seaport Therapeutics (2042347) Issuer
Zohar Daphne (1727388) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/30/2026 7:18 PM
PETERSON SANDRA E (1192752) Reporting
Seaport Therapeutics (2042347) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/30/2026 7:04 PM
Loebel Antony (1818770) Reporting
Seaport Therapeutics (2042347) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/30/2026 7:05 PM
HOMBACH ROBERT J. (1496182) Reporting
Seaport Therapeutics (2042347) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/30/2026 7:05 PM
Chen Michael Cunyuan (2127529) Reporting
Seaport Therapeutics (2042347) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/30/2026 5:03 PM
Seaport Therapeutics (2042347) Filer
Form S-1MEF
04/28/2026 3:06 PM
Seaport Therapeutics (2042347) Filer
Form 8-A12B
04/27/2026 5:06 AM
Seaport Therapeutics (2042347) Filer
Form S-1/A
(Data available from 1/1/2016 forward)

Seaport Therapeutics SEC Filings - Frequently Asked Questions

Seaport Therapeutics (SPTX) has submitted 33+ filings to the SEC since 2024. You can browse the complete history or filter by form type using the tools above.

The most recent filing was a Form 4 submitted on May 4, 2026. This was an insider ownership change filed by 4 - Seaport Therapeutics, Inc. (0002042347) (Issuer).

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:SPTX) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners